Harvard Apparatus Regenerative Technology is a biotechnology firm developing esophageal implants for patients battling threatening condition
Harvard Apparatus Regenerative Technology has raised $700K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Harvard Apparatus Regenerative Technology's investors include Connecticut Children’s Medical Center, Bin Zhao.
Harvard Apparatus Regenerative Technology is headquartered in Holliston, United States.
Harvard Apparatus Regenerative Technology is a biotechnology firm developing esophageal implants for patients battling threatening condition
Harvard Apparatus Regenerative Technology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Harvard Apparatus Regenerative Technology — Funding & Investors." VCBacked, January 6, 2026, https://www.vcbacked.co/company/harvard-apparatus-regenerative-technology. Accessed November 12, 2026.
VCBacked. (2026). Harvard Apparatus Regenerative Technology — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/harvard-apparatus-regenerative-technology
{{cite web |title=Harvard Apparatus Regenerative Technology — Funding & Investors |url=https://www.vcbacked.co/company/harvard-apparatus-regenerative-technology |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Harvard Apparatus Regenerative Technology? Request a listing update